Skip to main content

Advertisement

Table 3 Demographic and clinical characteristics in the study population at enrolment (n = 63)

From: Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses

Groups a 0 1 2 3 4 5 6 Total
  EcoVag® Lc4R5 Lc23B33 Lc21M49 Lg14869 Lg14869 LaciBios®  
  Lg 14869 Lg 20M39 Lg 6M9 Lg 6M9 Lr 14870 Lr 14870 Lr GR-1  
  Lr 14870 Lj 22B42 Lj 12B1 Lc 8R6 Lg 15527 Lg 15527 Lr RC-14  
  Vaginal Vaginal Vaginal Vaginal Vaginal Oral Oral  
  n = 9 n = 12 n = 10 n = 10 n = 9 n = 4 n = 9 n = 63
Mean age (range) 34.2 (19-55) 36.6 (26-48) 35.3 (25-45) 32.7 (25-39) 33.3 (21-46) 33.0 (25-38) 34.7 (21-45) 34.2 (19-55)
Patients with history of BV (no.) 3 6 5 5 3 0 1 23 (36.5%)
Patients with Mobiluncus on microscopy (no.) 4 6 5 3 4 2 2 26 (41.3%)
Length of symptoms of BV (months, mean and range)c 10.7 (1-24) 10.7 (1-48) 14.1 (1-60) 7.9 (1-48) 18.3 (2-60) 3.3 (2-6) 9.5 (1-24) 11.3 (1-60)
Patients with new relation (no.) 8 6 (2 divorced) 8 (1 divorced) 6 (2 divorced) 6 3 (1 divorced) 4 36 (57.1%)
New relation before symptoms appear (no.) 8 6 8 6 6 3 3 35 (55.6%)
Length of symptoms of BV among women with new relation (months, mean and range) 10.5(1-24) 6.5 (1-12) 14.4 (1-60) 4.5 (2-11) 11.3 (2-46) 3.3 (2-6) 11.2 (1-24) 8.2 (1-46)
  1. a Each group are given capsules with a mix of two or three Lactobacillus strains: Lg, L. gasseri; Lr, L. rhamnosus; Lc, L. crispatus; Lj, L. jenseneii
  2. b Capsules contain the two strains from EcoVag® plus an additional strain, L. gasseri DSM 15527, belonging to Bifodan A/S
  3. c One patient in group 3, 5, 6 and two patients in group 4 could not give any information since how long time she had symptoms of BV.